- Press Release -

Rockville, Md. The global lung cancer diagnostics market is set to expand at a 7.3% CAGR through 2022, according to Fact.MR, as new biomarker tests and broader screening reshape how the disease is caught. Blood-based methods using DNA methylation markers, such as the test launched by Epigenomics AG, point toward earlier detection, and early results have encouraged wider use.

North America carries the market, CA tests lead by type, and hospital-associated labs handle the largest share of testing. Awareness campaigns are widening the funnel of patients screened, with initiatives like the United Kingdom's lung cancer awareness month, backed by the Roy Castle Lung Cancer Foundation, lifting detection rates.

Tests, Settings and Indications

CA tests remain the workhorse of lung cancer diagnosis and are expected to reach US$ 889.3 Mn by 2022. The sharper growth, though, belongs to angiogenesis inhibitor tests, which lead the market on pace, followed by HER2 tests, while ALK testing stays a smaller contributor. By setting, hospital-associated labs are the most lucrative end user, independent diagnostic laboratories rank second, and cancer research institutes grow the quickest. Non-small cell lung cancer accounts for the largest revenue by indication, even as small cell lung cancer, from a low base, expands fastest.

North America stays dominant and is set to pass US$ 1 Bn by 2022, with Europe holding second place at a high single-digit pace.

Biomarkers Reshape Detection

The through-line is personalised medicine. A deepening pipeline of lung cancer-specific biomarkers is steering diagnosis toward tailored treatment, and manufacturers are racing to validate tests that catch malignancies earlier. Combined with public and private awareness drives, that pipeline is expected to keep demand climbing through the forecast period.

Suppliers and Their Playbook

The field brings together sequencing specialists, diagnostics majors and molecular testing firms.

• Illumina, Inc., Thermo Fischer Scientific, Inc., Quest Diagnostics Incorporated, NanoString Technologies, Inc., Myriad Genetics, Inc., Roche Holding AG, Abbott Laboratories, QIAGEN N.V., NeoGenomics Laboratories, Inc., and Danaher Corporation are among the key players in the report.

Reading the Market for Decisions

For diagnostics firms, the pull toward biomarker-driven tests and personalised treatment marks where to invest. Investors get a market with a firm clinical tailwind and steady growth. Procurement and lab teams can plan around hospital labs leading demand, CA tests carrying volume, and North America offering the largest opportunity through 2022.

About the Report

Fact.MR's study covers the global lung cancer diagnostics market for the 2017 to 2022 forecast period, with segmentation by test type, end user, indication and region. It sizes each segment, maps the competitive field, and weighs the clinical and awareness forces shaping demand. Further detail is available in the lung cancer diagnostics market report.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. The firm is known for its syndicated research, custom research and consulting solutions, helping clients make decisions on demand, competition, investment, procurement and future growth.